Rituximab and Fludarabine Combination Produces Long-Term Remissions in CLL
Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate
XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study
Study Suggests Biomarker For Resistance to Tamoxifen
Radiation, Tamoxifen After Surgery Reduce Breast Cancer Occurrence
Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint
Patients Who Smoke In Treatment Do Worse Than Those Who Quit
Dendritic Cell Vaccine May Boost Median Survival
Decline In Breast Cancer May Be Related to Drop In HT
Triple-Negative Breast Cancer Increases With Number of Births
PSA Velocity Poor Predictor Of Prostate Cancer Occurrence
Statins Associated With Lower Risk Of High-Grade Prostate Cancer
Mentholated Cigarettes Cause No More Lung Cancer, Deaths
Clinical Trials Approved By NCI CTEP Last Month
FDA Approves BMS’s Yervoy For Metastatic Melanoma
Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- In the Headlines: Is oncology ready to move away from animal testing?
- Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out
- Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care?
